These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
288 related articles for article (PubMed ID: 34805958)
1. Advances in locoregional therapy for hepatocellular carcinoma combined with immunotherapy and targeted therapy. Xue J; Ni H; Wang F; Xu K; Niu M J Interv Med; 2021 Aug; 4(3):105-113. PubMed ID: 34805958 [TBL] [Abstract][Full Text] [Related]
2. Role of locoregional therapies in the wake of systemic therapy. Palmer DH; Malagari K; Kulik LM J Hepatol; 2020 Feb; 72(2):277-287. PubMed ID: 31954492 [TBL] [Abstract][Full Text] [Related]
3. Interventional Radiology Image-Guided Locoregional Therapies (LRTs) and Immunotherapy for the Treatment of HCC. Biondetti P; Saggiante L; Ierardi AM; Iavarone M; Sangiovanni A; Pesapane F; Fumarola EM; Lampertico P; Carrafiello G Cancers (Basel); 2021 Nov; 13(22):. PubMed ID: 34830949 [TBL] [Abstract][Full Text] [Related]
4. Clinical trials of combined molecular targeted therapy and locoregional therapy in hepatocellular carcinoma: past, present, and future. Kim HY; Park JW Liver Cancer; 2014 Mar; 3(1):9-17. PubMed ID: 24804173 [TBL] [Abstract][Full Text] [Related]
5. New insights into mechanisms and interventions of locoregional therapies for hepatocellular carcinoma. Liu H; Wang C; Wang R; Cao H; Cao Y; Huang T; Lu Z; Xiao H; Hu M; Wang H; Zhao J Chin J Cancer Res; 2024 Apr; 36(2):167-194. PubMed ID: 38751435 [TBL] [Abstract][Full Text] [Related]
6. Locoregional therapies for hepatocellular carcinoma: The current status and future perspectives. Chen JJ; Jin ZC; Zhong BY; Fan W; Zhang WH; Luo B; Wang YQ; Teng GJ; Zhu HD United European Gastroenterol J; 2024 Mar; 12(2):226-239. PubMed ID: 38372444 [TBL] [Abstract][Full Text] [Related]
7. Research Progresses of Targeted Therapy and Immunotherapy for Hepatocellular Carcinoma. Wang T; Zhang Q; Wang N; Liu Z; Zhang B; Zhao Y Curr Med Chem; 2021; 28(16):3107-3146. PubMed ID: 33050856 [TBL] [Abstract][Full Text] [Related]
8. The Immune Modulation Effect of Locoregional Therapies and Its Potential Synergy with Immunotherapy in Hepatocellular Carcinoma. Singh P; Toom S; Avula A; Kumar V; Rahma OE J Hepatocell Carcinoma; 2020; 7():11-17. PubMed ID: 32104669 [TBL] [Abstract][Full Text] [Related]
9. The immune response of hepatocellular carcinoma after locoregional and systemic therapies: The available combination option for immunotherapy. Duan Y; Zhang H; Tan T; Ye W; Yin K; Yu Y; Kang M; Yang J; Liao R Biosci Trends; 2024 Jan; 17(6):427-444. PubMed ID: 37981319 [TBL] [Abstract][Full Text] [Related]
10. Emerging Opportunities for Combining Locoregional Therapy with Immune Checkpoint Inhibitors in Hepatocellular Carcinoma. Zeng P; Shen D; Zeng CH; Chang XF; Teng GJ Curr Oncol Rep; 2020 Jun; 22(8):76. PubMed ID: 32596779 [TBL] [Abstract][Full Text] [Related]
11. Retrospective analysis of the immunogenic effects of intra-arterial locoregional therapies in hepatocellular carcinoma: a rationale for combining selective internal radiation therapy (SIRT) and immunotherapy. Craciun L; de Wind R; Demetter P; Lucidi V; Bohlok A; Michiels S; Bouazza F; Vouche M; Tancredi I; Verset G; Garaud S; Naveaux C; Galdon MG; Gallo KW; Hendlisz A; Derijckere ID; Flamen P; Larsimont D; Donckier V BMC Cancer; 2020 Feb; 20(1):135. PubMed ID: 32075608 [TBL] [Abstract][Full Text] [Related]
13. Immune Responses Following Locoregional Treatment for Hepatocellular Carcinoma: Possible Roles of Adjuvant Immunotherapy. Han JW; Yoon SK Pharmaceutics; 2021 Sep; 13(9):. PubMed ID: 34575463 [TBL] [Abstract][Full Text] [Related]
14. Locoregional Combined With Systemic Therapies for Advanced Hepatocellular Carcinoma: An Inevitable Trend of Rapid Development. Li X; Wang Y; Ye X; Liang P Front Mol Biosci; 2021; 8():635243. PubMed ID: 33928118 [TBL] [Abstract][Full Text] [Related]
15. Advances of Targeted Therapy for Hepatocellular Carcinoma. Niu M; Yi M; Li N; Wu K; Wu K Front Oncol; 2021; 11():719896. PubMed ID: 34381735 [TBL] [Abstract][Full Text] [Related]
16. Locoregional Therapy, Immunotherapy and the Combination in Hepatocellular Carcinoma: Future Directions. Dendy MS; Ludwig JM; Stein SM; Kim HS Liver Cancer; 2019 Oct; 8(5):326-340. PubMed ID: 31768343 [TBL] [Abstract][Full Text] [Related]
17. Treatment options for unresectable HCC with a focus on SIRT with Yttrium-90 resin microspheres. Wang EA; Stein JP; Bellavia RJ; Broadwell SR Int J Clin Pract; 2017 Nov; 71(11):. PubMed ID: 28758319 [TBL] [Abstract][Full Text] [Related]
18. Recent Update on Immunotherapy and Its Combination With Interventional Therapies for Hepatocellular Carcinoma. Huang JT; Zhang S; Yang YH; Zhang ZC; Jiang N; Li WC; Shen J; Zhong BY; Zhu XL Clin Med Insights Oncol; 2022; 16():11795549221134832. PubMed ID: 36387611 [TBL] [Abstract][Full Text] [Related]
19. New Therapeutic Options for Advanced Hepatocellular Carcinoma. Ma YS; Liu JB; Wu TM; Fu D Cancer Control; 2020; 27(3):1073274820945975. PubMed ID: 32799550 [TBL] [Abstract][Full Text] [Related]
20. [Clinical advances in targeted therapy and immunotherapy for hepatocellular carcinoma]. Zhang DZ; Niu JQ Zhonghua Gan Zang Bing Za Zhi; 2019 Nov; 27(11):834-837. PubMed ID: 31941237 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]